Replies to post #114635 on Biotech Values

[DewDiligence]

If the situation were left on its own with no buyout, there would eventually be branded copaxone and one generic in different hands.

So far, so good.

If Teva bought MNTA and the FTC wanted to achieve the same situation as above, they would simply have Teva divest the generic.

I disagree that this would leave the same situation or even a comparable situation. Under your scenario, MNTA’s expertise would no longer be available to facilitate FDA approval of the Copaxone ANDA.